The estimated Net Worth of Christopher John Morl is at least $77.1 ezer dollars as of 15 January 2020. Christopher Morl owns over 15,034 units of Deciphera Pharmaceuticals Inc stock worth over $77,051 and over the last 7 years Christopher sold DCPH stock worth over $0.
Christopher has made over 6 trades of the Deciphera Pharmaceuticals Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently Christopher exercised 15,034 units of DCPH stock worth $59,384 on 15 January 2020.
The largest trade Christopher's ever made was exercising 16,137 units of Deciphera Pharmaceuticals Inc stock on 2 January 2020 worth over $63,741. On average, Christopher trades about 11,276 units every 5 days since 2017. As of 15 January 2020 Christopher still owns at least 3,011 units of Deciphera Pharmaceuticals Inc stock.
You can see the complete history of Christopher Morl stock trades at the bottom of the page.
Christopher's mailing address filed with the SEC is C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM, MA, 02451.
Over the last 7 years, insiders at Deciphera Pharmaceuticals Inc have traded over $25,274,872 worth of Deciphera Pharmaceuticals Inc stock and bought 3,916,644 units worth $57,831,028 . The most active insiders traders include Liam Ratcliffe, Associates Llc Brightstar és Ron Squarer. On average, Deciphera Pharmaceuticals Inc executives and independent directors trade stock every 17 days with the average trade being worth of $1,218,775. The most recent stock trade was executed by Thomas Patrick Kelly on 15 February 2024, trading 3,010 units of DCPH stock currently worth $47,016.
deciphera was established in 2003 based on a deep scientific understanding of kinase inhibitors and a team dedicated to developing sophisticated approaches to therapeutic targeting of kinases. with business and development operations based in boston, and dedicated research capabilities in close proximity to the university of kansas, deciphera has identified small molecule leads for over 50 kinase targets, and has developed a pipeline of small molecule drug candidates for a range of cancers.
Deciphera Pharmaceuticals Inc executives and other stock owners filed with the SEC include: